Treatment with the poly(ADP-ribose) polymerase inhibitor PJ-34 improves cerebromicrovascular endothelial function, neurovascular coupling responses and cognitive performance in aged mice, supporting the NAD+ depletion hypothesis of neurovascular aging.

Aging / physiology Animals Cerebrovascular Circulation / physiology Cognition / drug effects Disease Models, Animal Endothelium, Vascular / drug effects Memory, Short-Term / physiology Mice, Inbred C57BL Microcirculation / physiology NAD / deficiency Neurovascular Coupling / drug effects Nitric Oxide / metabolism Phenanthrenes / pharmacology Poly(ADP-ribose) Polymerase Inhibitors / pharmacology Vasodilation / physiology
Cellular energetics Endothelial dysfunction Functional hyperemia Microcirculation Oxidative stress ROS Senescence

Journal

GeroScience
ISSN: 2509-2723
Titre abrégé: Geroscience
Pays: Switzerland
ID NLM: 101686284

Informations de publication

Date de publication:
10 2019
Historique:
received: 26 08 2019
accepted: 10 09 2019
pubmed: 5 11 2019
medline: 22 5 2020
entrez: 4 11 2019
Statut: ppublish

Résumé

Adjustment of cerebral blood flow (CBF) to neuronal activity via neurovascular coupling (NVC) plays an important role in the maintenance of healthy cognitive function. Strong evidence demonstrates that age-related cerebromicrovascular endothelial dysfunction and consequential impairment of NVC responses contribute importantly to cognitive decline. Recent studies demonstrate that NAD

Identifiants

DOI: 10.1007/s11357-019-00101-2 PMID: 31679124 PMC: PMC6885075
pubmed: 31679124
doi: 10.1007/s11357-019-00101-2
pii: 10.1007/s11357-019-00101-2
pmc: PMC6885075
doi:

Substances chimiques

N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride 0
Phenanthrenes 0
Poly(ADP-ribose) Polymerase Inhibitors 0
NAD 0U46U6E8UK
Nitric Oxide 31C4KY9ESH

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

533-542

Subventions

Organisme : NIGMS NIH HHS
ID : U54 GM104938
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG050911
Pays : United States
Organisme : NINDS NIH HHS
ID : R01-NS100782
Pays : United States
Organisme : NIGMS NIH HHS
ID : P20 GM103447
Pays : United States
Organisme : NIA NIH HHS
ID : T32 AG052363
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG047879
Pays : United States
Organisme : NINDS NIH HHS
ID : R01-NS056218
Pays : United States
Organisme : NIA NIH HHS
ID : R01-AG038747
Pays : United States
Organisme : NIA NIH HHS
ID : R01-AG055395
Pays : United States
Organisme : NIA NIH HHS
ID : R01-AG047879
Pays : United States
Organisme : NIGMS NIH HHS
ID : P20 GM125528
Pays : United States

Références

Am J Physiol Heart Circ Physiol. 2008 Jun;294(6):H2721-35
pubmed: 18424637
Nat Rev Mol Cell Biol. 2016 Nov;17(11):679-690
pubmed: 27552971
J Cereb Blood Flow Metab. 2007 Dec;27(12):1908-18
pubmed: 17429347
Geroscience. 2017 Aug;39(4):457-463
pubmed: 28889220
Mech Ageing Dev. 2015 Mar;146-148:53-64
pubmed: 25881554
Am J Physiol Heart Circ Physiol. 2019 Jun 1;316(6):H1253-H1266
pubmed: 30875255
Geroscience. 2017 Feb;39(1):33-42
pubmed: 28299642
Cell Metab. 2008 Aug;8(2):157-68
pubmed: 18599363
Br J Pharmacol. 2002 Mar;135(6):1347-50
pubmed: 11906946
Cell Metab. 2016 Dec 13;24(6):795-806
pubmed: 28068222
Neurobiol Aging. 2013 Oct;34(10):2277-86
pubmed: 23628145
J Alzheimers Dis. 2016 Aug 10;54(1):307-24
pubmed: 27567805
Geroscience. 2017 Jun;39(3):347-356
pubmed: 28523599
J Pharmacol Exp Ther. 2004 Nov;311(2):485-91
pubmed: 15213249
Am J Physiol Heart Circ Physiol. 2015 Dec 1;309(11):H1837-45
pubmed: 26453330
Cell Metab. 2018 Mar 6;27(3):513-528
pubmed: 29249689
Cell. 2018 Mar 22;173(1):74-89.e20
pubmed: 29570999
Int J Mol Med. 2002 Jun;9(6):659-64
pubmed: 12011985
Aging Cell. 2019 Oct;18(5):e13016
pubmed: 31353811
Geroscience. 2019 Jun;41(3):341-349
pubmed: 31209739
Geroscience. 2017 Apr;39(2):129-145
pubmed: 28409331
Cell Metab. 2016 Jun 14;23(6):965-966
pubmed: 27304496
J Gerontol A Biol Sci Med Sci. 2012 Jun;67(6):553-64
pubmed: 22080499
Neurology. 2013 Sep 3;81(10):904-9
pubmed: 23925758
Circ Res. 2001 Oct 12;89(8):684-91
pubmed: 11597991
PLoS One. 2011 Apr 26;6(4):e19194
pubmed: 21541336
Geroscience. 2018 Jun 21;:null
pubmed: 29931650
Aging Cell. 2015 Dec;14(6):1034-44
pubmed: 26172407
Ann Neurol. 2011 Aug;70(2):213-20
pubmed: 21674588
Am J Physiol Heart Circ Physiol. 2008 Nov;295(5):H1882-94
pubmed: 18757483
Am J Physiol Heart Circ Physiol. 2014 Feb;306(3):H299-308
pubmed: 24322615
Geroscience. 2017 Dec;39(5-6):601-614
pubmed: 29243191
Nat Rev Drug Discov. 2005 May;4(5):421-40
pubmed: 15864271
Geroscience. 2017 Apr;39(2):187-198
pubmed: 28409332
Circulation. 2002 Nov 19;106(21):2680-6
pubmed: 12438293
Neuroimage. 2014 Jan 15;85 Pt 1:592-607
pubmed: 23664952
Circ Res. 2004 Nov 12;95(10):1019-26
pubmed: 15499027
Mech Ageing Dev. 2009 Aug;130(8):518-27
pubmed: 19549533
Geroscience. 2017 Jun;39(3):331-345
pubmed: 28477138
Redox Biol. 2019 Jun;24:101192
pubmed: 31015147
Neurosci Lett. 2009 Mar 6;452(1):17-22
pubmed: 19444940
Geroscience. 2018 Dec;40(5-6):437-452
pubmed: 30345481
Geroscience. 2019 Oct;41(5):619-630
pubmed: 31144244
Geroscience. 2017 Apr;39(2):147-160
pubmed: 28233247
Cell. 2013 Dec 19;155(7):1624-38
pubmed: 24360282
Funct Neurol. 2005 Jul-Sep;20(3):115-20
pubmed: 16324234
J Cereb Blood Flow Metab. 2015 Nov;35(11):1871-81
pubmed: 26174328
Geroscience. 2017 Aug;39(4):465-473
pubmed: 28578467
Aging Cell. 2018 Apr;17(2):
pubmed: 29405550
Exp Gerontol. 2017 Aug;94:52-58
pubmed: 27845201
J Cardiovasc Pharmacol. 2005 Mar;45(3):225-31
pubmed: 15725947
Cell Metab. 2011 Apr 6;13(4):461-468
pubmed: 21459330
PLoS One. 2012;7(7):e42357
pubmed: 22848760
Neurochem Res. 2012 Nov;37(11):2589-96
pubmed: 23076628

Auteurs

Stefano Tarantini (S)

Vascular Cognitive Impairment and Neurodegeneration Program, Oklahoma Center for Geroscience, Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma 975 NE 10th Street, BRC 1311, Oklahoma City, OK, 73104, USA.
International Training Program in Geroscience, Department of Public Health/Doctoral School of Basic and Translational Medicine, Semmelweis University, Budapest, Hungary.

Andriy Yabluchanskiy (A)

Vascular Cognitive Impairment and Neurodegeneration Program, Oklahoma Center for Geroscience, Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma 975 NE 10th Street, BRC 1311, Oklahoma City, OK, 73104, USA.

Tamas Csipo (T)

Vascular Cognitive Impairment and Neurodegeneration Program, Oklahoma Center for Geroscience, Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma 975 NE 10th Street, BRC 1311, Oklahoma City, OK, 73104, USA.
International Training Program in Geroscience, Department of Public Health/Doctoral School of Basic and Translational Medicine, Semmelweis University, Budapest, Hungary.
International Training Program in Geroscience, Division of Clinical Physiology, Faculty of Medicine, Research Center for Molecular Medicine, University of Debrecen, Debrecen, Hungary.

Gabor Fulop (G)

Vascular Cognitive Impairment and Neurodegeneration Program, Oklahoma Center for Geroscience, Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma 975 NE 10th Street, BRC 1311, Oklahoma City, OK, 73104, USA.
International Training Program in Geroscience, Division of Clinical Physiology, Faculty of Medicine, Research Center for Molecular Medicine, University of Debrecen, Debrecen, Hungary.
Heart and Vascular Center, Semmelweis University, Budapest, Hungary.

Tamas Kiss (T)

Vascular Cognitive Impairment and Neurodegeneration Program, Oklahoma Center for Geroscience, Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma 975 NE 10th Street, BRC 1311, Oklahoma City, OK, 73104, USA.
International Training Program in Geroscience, Department of Medical Physics and Informatics/Theoretical Medicine Doctoral School, University of Szeged, Szeged, Hungary.

Priya Balasubramanian (P)

Vascular Cognitive Impairment and Neurodegeneration Program, Oklahoma Center for Geroscience, Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma 975 NE 10th Street, BRC 1311, Oklahoma City, OK, 73104, USA.

Jordan DelFavero (J)

Vascular Cognitive Impairment and Neurodegeneration Program, Oklahoma Center for Geroscience, Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma 975 NE 10th Street, BRC 1311, Oklahoma City, OK, 73104, USA.

Chetan Ahire (C)

Vascular Cognitive Impairment and Neurodegeneration Program, Oklahoma Center for Geroscience, Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma 975 NE 10th Street, BRC 1311, Oklahoma City, OK, 73104, USA.

Anna Ungvari (A)

Vascular Cognitive Impairment and Neurodegeneration Program, Oklahoma Center for Geroscience, Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma 975 NE 10th Street, BRC 1311, Oklahoma City, OK, 73104, USA.

Ádám Nyúl-Tóth (Á)

Vascular Cognitive Impairment and Neurodegeneration Program, Oklahoma Center for Geroscience, Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma 975 NE 10th Street, BRC 1311, Oklahoma City, OK, 73104, USA.
Institute of Biophysics, Biological Research Centre, Hungarian Academy of Sciences, Szeged, Hungary.

Eszter Farkas (E)

International Training Program in Geroscience, Department of Medical Physics and Informatics/Theoretical Medicine Doctoral School, University of Szeged, Szeged, Hungary.

Zoltan Benyo (Z)

Institute of Clinical Experimental Research/Doctoral School of Basic and Translational Medicine, Semmelweis University, Budapest, Hungary.

Attila Tóth (A)

International Training Program in Geroscience, Division of Clinical Physiology, Faculty of Medicine, Research Center for Molecular Medicine, University of Debrecen, Debrecen, Hungary.

Anna Csiszar (A)

Vascular Cognitive Impairment and Neurodegeneration Program, Oklahoma Center for Geroscience, Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma 975 NE 10th Street, BRC 1311, Oklahoma City, OK, 73104, USA.
Institute of Clinical Experimental Research/Doctoral School of Basic and Translational Medicine, Semmelweis University, Budapest, Hungary.

Zoltan Ungvari (Z)

Vascular Cognitive Impairment and Neurodegeneration Program, Oklahoma Center for Geroscience, Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma 975 NE 10th Street, BRC 1311, Oklahoma City, OK, 73104, USA. zoltan-ungvari@ouhsc.edu.
International Training Program in Geroscience, Department of Public Health/Doctoral School of Basic and Translational Medicine, Semmelweis University, Budapest, Hungary. zoltan-ungvari@ouhsc.edu.
International Training Program in Geroscience, Department of Medical Physics and Informatics/Theoretical Medicine Doctoral School, University of Szeged, Szeged, Hungary. zoltan-ungvari@ouhsc.edu.
Department of Health Promotion Sciences, College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. zoltan-ungvari@ouhsc.edu.
ORCID: 0000-0002-6035-6039

Articles similaires

Evaluating the efficacy of telesurgery with dual console SSI Mantra Surgical Robotic System: experiment on animal model and clinical trials.

Sudhir Prem Srivastava, Vishwajyoti Pascual Srivastava, Avinesh Singh et al.
1.00
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell

FBXO22 inhibits colitis and colorectal carcinogenesis by regulating the degradation of the S2448-phosphorylated form of mTOR.

Minle Li, Xuan Chen, Pengfei Qu et al.
1.00
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Use of organic material provided by an automatic enrichment device by weaner pigs and its influence on tail lesions.

Philipp Heseker, Jeanette Probst, Stefanie Ammer et al.
1.00
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH

questionsmedicales.fr › Phénomènes physiologiques › Croissance et développement › Vieillissement › Treatment with the poly(ADP-ribose) polymerase...
questionsmedicales.fr › Eucaryotes › Animaux › Treatment with the poly(ADP-ribose) polymerase...
questionsmedicales.fr › Phénomènes physiologiques respiratoires et circulatoires › Phénomènes physiologiques cardiovasculaires › Circulation sanguine › Circulation cérébrovasculaire › Treatment with the poly(ADP-ribose) polymerase...
questionsmedicales.fr › Phénomènes psychologiques › Processus mentaux › Cognition › Treatment with the poly(ADP-ribose) polymerase...
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles biologiques › Modèles animaux de maladie humaine › Treatment with the poly(ADP-ribose) polymerase...
questionsmedicales.fr › Tissus › Épithélium › Endothélium › Endothélium vasculaire › Treatment with the poly(ADP-ribose) polymerase...
questionsmedicales.fr › Phénomènes psychologiques › Processus mentaux › Mémoire › Mémoire à court terme › Treatment with the poly(ADP-ribose) polymerase...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Lignées consanguines de souris › Souris de lignée C57BL › Treatment with the poly(ADP-ribose) polymerase...
questionsmedicales.fr › Phénomènes physiologiques respiratoires et circulatoires › Phénomènes physiologiques cardiovasculaires › Circulation sanguine › Microcirculation › Treatment with the poly(ADP-ribose) polymerase...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Nucléotides › Ribonucléotides › Nucléotides adényliques › NAD › Treatment with the poly(ADP-ribose) polymerase...
questionsmedicales.fr › Phénomènes physiologiques respiratoires et circulatoires › Phénomènes physiologiques cardiovasculaires › Circulation sanguine › Circulation cérébrovasculaire › Couplage neurovasculaire › Treatment with the poly(ADP-ribose) polymerase...
questionsmedicales.fr › Produits chimiques inorganiques › Composés de l'oxygène › Oxydes › Oxydes d'azote › Monoxyde d'azote › Treatment with the poly(ADP-ribose) polymerase...
questionsmedicales.fr › Composés polycycliques › Hydrocarbures aromatiques polycycliques › Phénanthrènes › Treatment with the poly(ADP-ribose) polymerase...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Inhibiteurs de poly(ADP-ribose) polymérases › Treatment with the poly(ADP-ribose) polymerase...
questionsmedicales.fr › Phénomènes physiologiques respiratoires et circulatoires › Phénomènes physiologiques cardiovasculaires › Hémodynamique › Vasodilatation › Treatment with the poly(ADP-ribose) polymerase...